Summary
MDGEF Chart
Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript
Medigene AG (OTCPK:MDGEF) Q2 2024 Earnings Conference Call August 14, 2024 9:30 AM ET Company Participants Pamela Keck - Head, IR Selwyn Ho - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Abhishek Raval - AlphaValue Operator Ladies and gentlemen, thank you for standing by.
Medigene AG (MDGEF) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Medigene AG Profile
| Biotechnology Industry | Healthcare Sector | Ralph Schafer CEO | OTC PINK Exchange | DE000A40ESG2 ISIN |
| DE Country | 87 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Medigene AG is a pioneer in the field of biotechnology with a laser focus on the development of innovative T-cell therapies for the treatment of cancer. This company leverages a comprehensive end-to-end platform to advance the development of T cell receptor engineered T cell (TCR-T) therapies tailored for multiple tumor indications. Established in 1994 and headquartered in Munich, Germany, Medigene AG has expanded its reach with operations across Germany, the United States, and Asia. The company's strategic commitments are evident in its partnerships with prominent entities like BioNTech, 2seventy bio, Inc., and the National Cancer Institute for the advancement of TCR-based immunotherapies and the exploration of new cell constructs for combating solid tumors.
Products and Services
- MDG1015:
A front-runner in Medigene's pipeline, MDG1015, represents a TCR-T therapy product designed for the treatment of multiple solid tumor indications. This product embodies the company's innovation in harnessing the power of T-cell receptor engineering to target and eliminate cancer cells effectively.
- MDG10xx:
Another valuable component of Medigene's arsenal against cancer, the MDG10xx series, is under development to address a range of solid tumors. While specific details about the targets and mechanism of action are under wraps, MDG10xx signifies Medigene's ongoing commitment to broadening its impact on cancer treatment.
- MDG1011:
MDG1011 stands as a promising TCR-T immunotherapy candidate, currently navigating the clinical development stages to treat blood cancers. This candidate showcases Medigene's capabilities in developing targeted therapies for hematological malignancies, with the potential to significantly improve patient outcomes.
- Dendritic Cell Vaccines:
Beyond TCR-T therapies, Medigene is exploring the potential of dendritic cell vaccines. These vaccines represent a different approach to cancer immunotherapy, focusing on stimulating the immune system to recognize and destroy tumor cells, further demonstrating Medigene's diverse strategies in combatting cancer.
